Analysis compares efficacy and safety outcomes of venetoclax treatment in real-world CLL patients versus randomized clinical trials, suggesting equivalency in results.
Key Points
Patients treated with venetoclax for chronic lymphocytic leukemia show similar outcomes regardless of treatment setting.
Both treatment cohorts exhibited acceptable tolerability and safety profiles to venetoclax with no significant differences observed.
Observational analysis included 112 patients treated either in the standard practice or through randomized clinical trials.
Findings indicate that real-world CLL patients have comparable safety and efficacy profiles to those reported in established RCTs.